Perrigo had its Relative Strength (RS) Rating upgraded from 70 to 73 Tuesday — a welcome improvement, but still below the 80 or better score you look for.
This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks tend to have an RS Rating north of 80 as they launch their biggest climbs. See if Perrigo can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
While now is not an ideal time to jump in, see if the stock goes on to offer and clear a proper buy point.
Earnings growth fell in the most recent quarter from 27% to 8%. But sales moved higher, from -3% to -2%.
The company holds the No. 5 rank among its peers in the Medical-Generic Drugs industry group. Haleon ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
